The estimated Net Worth of Bruce A Goldsmith is at least $769 Mille dollars as of 21 March 2022. Dr Goldsmith owns over 10,000 units of Passage Bio Inc stock worth over $12,307 and over the last 5 years he sold PASG stock worth over $0. In addition, he makes $756,923 as CEO e Pres & Director at Passage Bio Inc.
Dr has made over 3 trades of the Passage Bio Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently he bought 10,000 units of PASG stock worth $31,500 on 21 March 2022.
The largest trade he's ever made was buying 10,000 units of Passage Bio Inc stock on 21 March 2022 worth over $31,500. On average, Dr trades about 2,183 units every 125 days since 2020. As of 21 March 2022 he still owns at least 15,983 units of Passage Bio Inc stock.
You can see the complete history of Dr Goldsmith stock trades at the bottom of the page.
Dr. Bruce A. Goldsmith M.B.A., Ph.D. is the CEO, Pres & Director at Passage Bio Inc.
As the CEO e Pres & Director of Passage Bio Inc, the total compensation of Dr D at Passage Bio Inc is $756,923. There are no executives at Passage Bio Inc getting paid more.
Dr D is 55, he's been the CEO e Pres & Director of Passage Bio Inc since . There are 5 older and 4 younger executives at Passage Bio Inc. The oldest executive at Passage Bio Inc is Dr. James M. Wilson M.D., Ph.D., 66, who is the Co-Founder & Chief Scientific Advisor.
Bruce's mailing address filed with the SEC is ONE COMMERCE SQUARE, 2005 MARKET STREET, 39TH FLOOR, PHILADELPHIA, PA, 19103.
Over the last 5 years, insiders at Passage Bio Inc have traded over $535,533 worth of Passage Bio Inc stock and bought 4,392,148 units worth $41,339,284 . The most active insiders traders include Liam Ratcliffe, Advisors Llc Orbi Med Capit... e Thomas Woiwode. On average, Passage Bio Inc executives and independent directors trade stock every 37 days with the average trade being worth of $92,858. The most recent stock trade was executed by Kathleen Borthwick on 10 February 2024, trading 4,000 units of PASG stock currently worth $3,080.
passage bio, inc., a genetic medicines company, develops transformative therapies for rare monogenic central nervous system (cns) diseases. the company develops pbgm01, which utilizes a proprietary, aavhu68 capsid to deliver to the brain and peripheral tissues a functional glb1 gene encoding lysosomal acid beta-galactosidase (ã-gal) for infantile gm1; pbft02, which utilizes an aav1 capsid to deliver to the brain a functional granulin, or grn, gene encoding progranulin for the treatment of ftd caused by a deficiency of progranulin; and pbkr03, which utilizes a proprietary, aavhu68 capsid to deliver to the brain and peripheral tissues a functional galc gene encoding the hydrolytic enzyme galactosylceramidase, for infantile krabbe disease. it has a strategic research collaboration with the trustees of the university of pennsylvania's gene therapy program; and collaboration agreement, and a development services and clinical supply agreement with catalent maryland, inc. the company was fou
Passage Bio Inc executives and other stock owners filed with the SEC include: